TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00853385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP 690,550
Description: tablets 5 mg BID PO plus q2 week placebo SC injections for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: tablets 10 mg BID PO plus q2 week placebo SC injections for 12 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets BID PO advance to 5mg CP 690,550 BID at Month 3 or 6 visit plus q2 week placebo SC injections for 12 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets BID PO advance tablets to10mg CP 690,550 BID at Month 3 or 6 visit plus q2 week placebo SC injections for 12 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Biologic TNFi
Description: placebo tablets BID PO plus adalimumab 40 mg q2 week SC injections for 12 months
Study: NCT02799381

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimized antiparkinsonian treatment
Description: Dose levels of prescribed antiparkinsonian medications were individually optimized to their maximum therapeutic effect.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa-Carbidopa Intestinal Gel (LCIG)
Description: Dose levels were individually optimized.
Study: NCT01001104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265
Description: Administered by subcutaneous (SC) injection, once weekly (QW) for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265
Description: Administered by subcutaneous (SC) injection, once weekly (QW) for 12 weeks.
Study: NCT02799381

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CADD-Legacy ambulatory infusion pump
Description: (manufactured by Smiths Medical)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic gastrostomy tube
Description: (PEG tube)
Study: NCT01001104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265
Description: Administered by subcutaneous (SC) injection, once weekly (QW) for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by SC injection, QW for 12 weeks.
Study: NCT00820300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost-PPDS
Description: Control of IOP compared to baseline for the experimental doses of Latanoprost-PPDS for 4 months or until loss of efficacy.
Study: NCT05316870

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized anticoagulation management plan and process of atrial fibrillation in primary medical institutions
Description: Compared with the current anticoagulation management service, we pay more attention to early initiation of anticoagulant therapy and long-term follow-up management.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Conventional general practitioner management model
Description: The current general practitioner anticoagulation management model was continued in the control group.
Study: NCT01860508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed /carboplatin
Study: NCT04530851

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS
Description: * Counseling~* H2- antagonist and metroclopramide for prevent aspiration~* Drink clear liquid until 2 hour before surgery~* First generation cephalosporin in 60 minute before surgery~* Clorhexidine for skin cleansing and Povidine for vaginal cleansing~* Regional anesthesia~* Keep warming~* Blunt expansion of uterine incision~* Do not peritoneal suture and subcuticular suture if less than 2 cm~* Local wound anesthesia.~* Paracetamol and NSAIDs for for pain control~* Early remove catheter and ambulation~* 5-HT3 antagonist for prevent nausea
Study: NCT02799381

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jejunal extension tube
Description: (J-tube)
Study: NCT03195101

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transconjunctival orbitotomy approach
Description: approach the orbital tumor through an incision in the conjunctiva, This is followed by blunt dissection of the tenons capsule. A traction suture is applied over the corresponding rectus muscle to guide the globe toward the desired direction. The orbital fat is retracted by malleable retractor and blunt dissection through the orbital connective tissue continues until reaching the edge of the tumor. After the mass is exposed, a biopsy or complete resection of the mass is taken place
Study: NCT03368859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil - bolus
Description: Intravenous
Study: NCT03774095

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydrolyzed pine nut oil and olive oil
Description: Given 30 min prior to oral glucose tolerance test
Study: NCT02954042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pelvital probe
Description: Pelvital probe

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Probe
Description: Placebo Probe
Study: NCT03893344

Intervention type: DIAGNOSTIC_TEST
Intervention: detection of STAT4 gene
Description: Individuals within both groups will be subjected to STAT4 gene polymorphism typing using both PCR and flow cytometry from a peripheral blood sample

Intervention type: DIAGNOSTIC_TEST
Intervention: detection of STAT4 gene
Description: Individuals within both groups will be subjected to STAT4 gene polymorphism typing using both PCR and flow cytometry from a peripheral blood sample
Study: NCT02829944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01018446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
Study: NCT01556347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib, Thymoglobulin, Rituximab, Gamimune N, (IVIG), Plasmapheresis
Study: NCT00959374

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: V-Loc 180/90 Wound Closure Device
Description: Barbed absorbable suture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3-0 Monocryl Absorbable Sutures
Description: 3-0 Monocryl Absorbable Suture (non-barbed)
Study: NCT00641927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: 37.5 mg - 375 mg daily, 12 Weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium Carbonate
Description: 300 mg - 2100 mg daily, 12 weeks
Study: NCT02708082

Intervention type: DEVICE
Intervention: OCT scanning and HFA perimetry
Description: Imaging of the optic nerve and nerve fiber layer / measurement of visual field
Study: NCT02713256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFZ533
Description: CFZ533 intravenously over approximately one hour
Study: NCT03102840

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasopharyngeal swab
Description: Nasopharyngeal swab will be performed in all participants

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasopharyngeal swab
Description: Nasopharyngeal swab will be performed in all participants

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sampling
Description: Blood sampling will be done by finger-prick in a sub-set of participants
Study: NCT01422967

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Balance and muscle strength
Description: Balance test: bi and unipodal balance in the place force Muscle strength: bilateral test of knee in dynamometer isokinetic

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Balance and muscle strength
Description: Balance test: bi and unipodal balance in the place force Muscle strength: bilateral test of knee in dynamometer isokinetic
Study: NCT01397825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib (MLN8237)
Description: Alisertib (MLN8237) enteric coated tablet (ECT).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib (MLN8237)
Description: Alisertib (MLN8237) enteric coated tablet (ECT).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib (MLN8237)
Description: Alisertib (MLN8237) enteric coated tablet (ECT).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib (MLN8237)
Description: Alisertib (MLN8237) enteric coated tablet (ECT).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib (MLN8237)
Description: Alisertib (MLN8237) enteric coated tablet (ECT).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine IV Infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine IV Infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine IV Infusion.
Study: NCT03368859

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil - bolus
Description: Intravenous
Study: NCT03483194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kalinox
Description: Usually take care of by a gas mixture composed of 50% Nitrous Oxide, 50% Oxygen for the medical procedure (osteo-medullary biopsy)
Study: NCT03650985

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fetoscope technique
Description: Intrauterine intervention with fetoscope technique will be applied to treat complex twin diseases with intention to improve the prognosis of patients.
Study: NCT01421264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 300mg capsules by mouth
Study: NCT03082872

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cemented K-wire
Description: Fracture of proximal phalanx was treated with Cemented K-wire.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cemented K-wire
Description: Fracture of proximal phalanx was treated with Cemented K-wire.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transfixion Pinning
Description: Fracture of proximal phalanx was treated with transfixion pinning.
Study: NCT03368859

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Intravenous
Study: NCT03082872

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transfixion Pinning
Description: Fracture of proximal phalanx was treated with transfixion pinning.
Study: NCT02400359

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorcaserin HCl
Description: Lorcaserin is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is a placebo oral pill that is a visual replica of the Lorcaserin medication but with no active ingredients.
Study: NCT01666899

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin and blood vessel procedures
Description: Biopsies, skin blood flow studies and ultrasound studies will be performed as described.
Study: NCT02758496

Intervention type: OTHER
Intervention: MeRT Efficacy Chart Review
Description: There will be not intervention. This is a chart review.

Intervention type: OTHER
Intervention: MeRT Efficacy Chart Review
Description: There will be not intervention. This is a chart review.
Study: NCT03079466

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: This is a randomized study where patients are included consecutively under a randomization order that will be given to the investigators. Patients will continue to be treated with CPAP and other treatment with no CPAP for a duration of 3 months and with intention-to-treat analysis And by protocol.
Study: NCT04086979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parental Friendship Coaching
Description: In this condition, therapists instructed parents in ways to coach their children to display better friendship behaviors using skills teaching, role play, active practice, and homework. This is a 10 week group intervention.
Study: NCT03079466

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: CPAP
Description: This is a randomized study where patients are included consecutively under a randomization order that will be given to the investigators. Patients will continue to be treated with CPAP and other treatment with no CPAP for a duration of 3 months and with intention-to-treat analysis And by protocol.
Study: NCT03974035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second infiltration pre-extubation with ropivacaine
Description: The surgeon will proceed firstly with pre-incisional infiltration with lidocaine and adrenaline after intubation, and secondly with pre-extubation infiltration with ropivacaine at the intraoral and intranasal submucosal level in the maxilla and jaw to block the terminal branches of the maxillary and mandibular nerve
Study: NCT01209793

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REGN846
Description: 5 IV cohorts (Dose 1, 2, 3, 4, 5)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REGN846
Description: 5 IV cohorts (Dose 1, 2, 3, 4, 5)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REGN846
Description: 5 IV cohorts (Dose 1, 2, 3, 4, 5)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REGN846
Description: 5 IV cohorts (Dose 1, 2, 3, 4, 5)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REGN846
Description: 5 IV cohorts (Dose 1, 2, 3, 4, 5)
Study: NCT03492372

Intervention type: OTHER
Intervention: Waste tissues are collected at the time of spinal surgery.
Description: This is a single visit study. Waste tissues are collected at the time of spinal surgery.
Study: NCT03502395

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: ): Patients were received intravenous 1 mg/kg of 2 % lidocaine as a loading dose (just before induction of anesthesia) then received 2mg/kg /h lidocaine as maintenance dose (with maximum of 200 mg/h) till the end of the operation (skin closure).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: A standardized equal volume of intravenous bolus dose of normal saline was given as loading dose then normal saline was administered on an equal rate of infusion.
Study: NCT00582673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03224494

Intervention type: DEVICE
Group type: OTHER
Intervention: Rapid Barostat Bag
Description: Both healthy controls (n= 100) and IBS patients (n=100) will undergo anorectal studies using a Rapid barostat bag catheter.

Intervention type: DEVICE
Group type: OTHER
Intervention: Rapid Barostat Bag
Description: Both healthy controls (n= 100) and IBS patients (n=100) will undergo anorectal studies using a Rapid barostat bag catheter.

Intervention type: OTHER
Group type: OTHER
Intervention: IBS severity scoring system questionnaire (IBS-SSS)
Description: We will correlate the changes to IBS symptoms using the IBS severity scoring system questionnaire (IBS-SSS). The questionnaire will be administered twice for IBS patients who have consented to return for a second study visit, at each of the two RBB studies.

Intervention type: OTHER
Group type: OTHER
Intervention: IBS severity scoring system questionnaire (IBS-SSS)
Description: We will correlate the changes to IBS symptoms using the IBS severity scoring system questionnaire (IBS-SSS). The questionnaire will be administered twice for IBS patients who have consented to return for a second study visit, at each of the two RBB studies.

Intervention type: OTHER
Group type: OTHER
Intervention: HAD scale questionnaire
Description: It is a validated anxiety and depression questionnaire

Intervention type: OTHER
Group type: OTHER
Intervention: HAD scale questionnaire
Description: It is a validated anxiety and depression questionnaire
Study: NCT03657953

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: surgical approach

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: surgical approach

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: surgical approach
Study: NCT01397825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine IV Infusion.
Study: NCT04086979

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coping with ADHD through Relationships and Education
Description: In this condition, the therapist provided parents with psychoeducation about ADHD and friendship difficulties, and encouraged them to apply this information to their child and to support one another with tips about how to address these problems. This is a 10 week group intervention.
Study: NCT01354054

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Frequency TENS
Description: 100 usec, 100 Hz, pulse amplitude motor - 10%, 30-40 minutes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low frequency TENS
Description: 100 usec, 4 Hz, pulse amplitude motor - 10%, 30-40 minutes
Study: NCT03093519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK6640
Description: Intravenous administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous administration
Study: NCT00262288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: i.v. recombinant human C1 inhibitor
Study: NCT02953093

Intervention type: DRUG
Group type: OTHER
Intervention: Acarbose
Description: see arm description
Study: NCT03368859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil - infusion
Description: Intravenous
Study: NCT01354054

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placebo TENS
Description: 100 usec, 100 Hz, motor - 10%, pulse amplitude adjusted and maintained for 30 seconds then ramping down to zero in 15 seconds
Study: NCT02925533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B-701
Description: B-701 is a phage-derived, affinity-matured, human monoclonal antibody (mAb) specific for FGFR3. It is based on a human immunoglobulin G1 (IgG1) framework containing heavy chain VHIII and light chain VκI subgroup sequences.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is an mAb that binds to the programmed cell death protein 1 (PD-1) receptor and blocks its interaction with programmed death-ligand 1 (PD-L1) and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.
Study: NCT01877733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximal strength training
Study: NCT02895997

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Travel Telehealth Delivery
Description: Clinical Operations Room (COR) staff will travel to Sydney Australia to deliver telehealth to patients in Georgia United States. Upon arrival, participants will have eight nights and seven days free of clinical responsibilities. Thereafter, each participant will work four consecutive days of 12 hour shifts followed by four consecutive days with no clinical assignment. The following week, participants will work three consecutive days of 12 hour shifts followed by four consecutive days with no clinical assignment. Upon return to the USA, participants will have a week free of clinical responsibilities.
Study: NCT01020006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-27483
Description: Part A: Closed to enrollment.Part B: Approximately 20 patients will be randomized to the control arm that will receive a standard regimen of gemcitabine and 20 patients will be randomized to the PCI-27483 arm and treated with both gemcitabine and PCI-27483. PCI-27483 will be administered as subcutaneous (SC) injections, nominally at a dosage of 1.2 mg/kg BID. Patients receiving PCI-27483 with a tumor response or stable disease at 12 weeks will have the option to continue PCI-27483 treatment until disease progression or the investigator considers the study treatment no longer tolerable. Treatment with gemcitabine may continue per standard of care.~All evaluable patients will roll over into Part C at week 16 (Day 113±5). If 2 consecutive INRs at 2 hours postdose are \>3.50,a reduced dosage will be calculated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study: NCT01661088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: Starting dose levels as following:~Oxaliplatin 85mg/m2 intravenously over 120 minutes on day 1. Irinotecan 180mg/m2 intravenously over 90 minutes on day 1. NOTE: patients homozygous for the UGT1A1 (TA)7 promoter allele will be treated at an initial lower dose 140mg/m2 (please see Section 6.3.a) Leucovorin 400mg/m2 intravenously over 90 minutes on day 1. 5FU 400mg/m2 as bolus intravenous injection following leucovorin on day 1. 5FU 2,400mg/m2 infused intravenously as a continuous infusion over 46 hours following the bolus 5FU, beginning on day 1.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Description: 50.0Gy in 2.0Gy per fraction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Exploration
Description: Patients without metastatic disease will be offered surgical exploration.
Study: NCT03368859

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil - infusion
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-165
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Intravenous
Study: NCT02698410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide (Autogel formulation) and Temozolomide
Study: NCT01901224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo